65,437 trials
Vitamin D Deficiency
Primary: Change in LDL Cholesterol Level — 3.2; 1.4 mg/dl
Rheumatoid Arthritis
Primary: Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and AEs of Special Interest (AESIs) — 75; 0; 0 percentage of participants
Neuropathic Diabetic Ulcer - Foot
Primary: Incidence of Complete Wound Closure — 79; 49 participants
Extrahepatic Bile Duct Cancer · Gallbladder Cancer
Primary: Stratum-specific (R0 and R1) 2-year Overall Survival — 67; 60 percentage of participants
Estrogen Receptor Positive Breast Cancer · Progesterone Receptor Positive Tumor · Recurrent Breast Carcinoma
Primary: Disease-free Survival — 84.7; 86.6; 89 percentage of participants — p=0.1
Alcohol Intake · Sleep Deprivation
Primary: Aerobic Performance — 172; 173; 175; 176 bpm
Influenza
Primary: Seroconversion to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine — 66.7; 63.5; 72.1; 57.0 percentage of participants
Depression · Dementia
Primary: Depression — 48 participants
Depression, Postpartum
Primary: Hamilton Depression Rating Scale (HAM-D) — 22.0; 21.8; 22.0; 8.8 units on a scale
Kidney Stones
Primary: Radiation Exposure (Dose-Length-Product) at Baseline — 293.5; 482.1; 915.99 mGy*cm
Psoriasis
Primary: Investigator Global Assessment — 1.13 units on a scale
Chronic Hepatitis C Infection
Primary: Change in HCV RNA Viral Load — .24; .08 log(IU/mL) — p=0.05
Breast Cancer
Primary: Proportion of Patients Who Are Progression-free (CR, PR and Stable Disease) — 4 participants
Restless Legs Syndrome
Primary: Number of Subjects Withdrawn Due to An Adverse Event (AE) From Visit 1 (Day 1) Through End of Study — 3 subjects
Pain
Primary: Pain Score on the Numeric Rating Scale (NRS) — 2.3; 4.3 NRS